TRIM21—From intracellular immunity to therapy

Frontiers in Immunology

Volumn 10, Issue AUG, 2019, Pages

  Foss, Stian ^a,b,c   Bottermann, Maria ^d   Jonsson, Alexandra ^b,c,d   Sandlie, Inger ^a,b   James, Leo C ^d   Andersen, Jan Terje ^b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Antibody; Gene therapy; Infection; TRIM21; Virus

Indexed keywords

ALPHAVBETA5 INTEGRIN; B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C2A; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; DYNEIN ADENOSINE TRIPHOSPHATASE; FC RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INTERFERON; NEUTRALIZING ANTIBODY; OVALBUMIN; PROTEASOME; SMALL INTERFERING RNA; TAU PROTEIN; TRANSCRIPTOME; TRIPARTITE MOTIF CONTAINING PROTEIN 2; TRIPARTITE MOTIF PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOSIN CONTAINING PROTEIN; VITRONECTIN RECEPTOR; ANTIBODY; COMPLEMENT; RIBONUCLEOPROTEIN; SS-A ANTIGEN; VIRUS ANTIBODY;

ANTIBODY ENGINEERING; ANTIBODY RESPONSE; AUTOPHAGY; BINDING AFFINITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DRUG POTENTIATION; ELECTROPORATION; ENDOCYTOSIS; ENDOPLASMIC RETICULUM STRESS; EXOCYTOSIS; FOOT AND MOUTH DISEASE VIRUS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PRY-SPRY DOMAIN; REVIEW; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; SYNERGISTIC EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR IMMUNITY; VIRUS NEUTRALIZATION; VIRUS REPLICATION; CHEMISTRY; CYTOPLASM; GENETIC ENGINEERING; IMMUNITY; IMMUNOLOGY; INTRACELLULAR SPACE; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COMPLEMENT SYSTEM PROTEINS; CYTOPLASM; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; IMMUNITY; IMMUNITY, INNATE; INTRACELLULAR SPACE; MOLECULAR TARGETED THERAPY; RIBONUCLEOPROTEINS; SIGNAL TRANSDUCTION;

EID: 85072048851     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2019.02049     Document Type: Review

References (125)

1. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. (2002) 2:706–13. doi: 10.1038/nri891
2. Walker LM, Burton DR. Passive immunotherapy of viral infections: ’super-antibodies’ enter the fray. Nat Rev Immunol. (2018) 18:297– 308. doi: 10.1038/nri.2017.148
3. Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. (2018) 19:1179–88. doi: 10.1038/s41590-018-0235-7
4. Corti D, Cameroni E, Guarino B, Kallewaard NL, Zhu Q, Lanzavecchia A. Tackling influenza with broadly neutralizing antibodies. Curr Opin Virol. (2017) 24:60–9. doi: 10.1016/j.coviro.2017.03.002
5. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. (2014) 158:1243–53. doi: 10.1016/j.cell.2014. 08.023
6. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med. (2014) 20:143–51. doi: 10.1038/nm.3443
7. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA. (2010) 107:19985– 90. doi: 10.1073/pnas.1014074107
8. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol. (2002) 83 (Pt 9):2091– 108. doi: 10.1099/0022-1317-83-9-2091
9. Leung DT, Tam FC, Ma CH, Chan PK, Cheung JL, Niu H, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis. (2004) 190:379–86. doi: 10.1086/422040
10. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. (2005) 174:7179–85. doi: 10.4049/jimmunol.174.11.7179
11. Schrader JW, McLean GR. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies. Immunol Lett. (2007) 112:58–60. doi: 10.1016/j.imlet.2007.07.001
12. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. (2013) 14:327–36. doi: 10.1038/ni.2548
13. Rakebrandt N, Lentes S, Neumann H, James LC, Neumann-Staubitz P. Antibody-and TRIM21-dependent intracellular restriction of Salmonella enterica. Pathog Dis. (2014) 72:131–7. doi: 10.1111/2049-632X.12192
14. Randow F, MacMicking JD, James LC. Cellular self-defense: how cell-autonomous immunity protects against pathogens. Science. (2013) 340:701– 6. doi: 10.1126/science.1233028
15. Bottermann M, James LC. Intracellular antiviral immunity. Adv Virus Res. (2018) 100:309–54. doi: 10.1016/bs.aivir.2018.01.002
16. Odendall C, Kagan JC. Activation and pathogenic manipulation of the sensors of the innate immune system. Microbes Infect. (2017) 19:229– 37. doi: 10.1016/j.micinf.2017.01.003
17. Tam JC, Bidgood SR, McEwan WA, James LC. Intracellular sensing of complement C3 activates cell autonomous immunity. Science. (2014) 345:1256070. doi: 10.1126/science.1256070
18. Bottermann M, Foss S, Caddy SL, Clift D, van Tienen LM, Vaysburd M, et al. Complement C4 prevents viral infection through capsid inactivation. Cell Host Microbe. (2019) 25:617–29.e7. doi: 10.1016/j.chom.2019.02.016
19. Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O’Connell K, et al. TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination. Proc Natl Acad Sci USA. (2018) 115:10440–5. doi: 10.1073/pnas.1806314115
20. McEwan WA, Falcon B, Vaysburd M, Clift D, Oblak AL, Ghetti B, et al. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci USA. (2017) 114:574–9. doi: 10.1073/pnas.1607215114
21. Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, et al. A method for the acute and rapid degradation of endogenous proteins. Cell. (2017) 171:1692–706 e18. doi: 10.1016/j.cell.2017.10.033
22. Clift D, So C, McEwan WA, James LC, Schuh M. Acute and rapid degradation of endogenous proteins by Trim-Away. Nat Protoc. (2018) 13:2149–75. doi: 10.1038/s41596-018-0028-3
23. Ozato K, Shin DM, Chang TH, Morse HC, III. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. (2008) 8:849–60. doi: 10.1038/nri2413
24. Freemont PS. RING for destruction? Curr Biol. (2000) 10:R84– 7. doi: 10.1016/S0960-9822(00)00287-6
25. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci USA. (2007) 104:6200–5. doi: 10.1073/pnas.0609174104
26. Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci USA. (2008) 105:6045–50. doi: 10.1073/pnas.0800159105
27. Ben-Chetrit E, Chan EK, Sullivan KF, Tan EM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med. (1988) 167:1560– 71. doi: 10.1084/jem.167.5.1560
28. Ben-Chetrit E, Fox RI, Tan EM. Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjogren’s syndrome. Arthritis Rheum. (1990) 33:349– 55. doi: 10.1002/art.1780330307
29. McEwan WA, Mallery DL, Rhodes DA, Trowsdale J, James LC. Intracellular antibody-mediated immunity and the role of TRIM21. Bioessays. (2011) 33:803–9. doi: 10.1002/bies.201100093
30. Ottosson L, Hennig J, Espinosa A, Brauner S, Wahren-Herlenius M, Sunnerhagen M. Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjogren’s syndrome. Mol Immunol. (2006) 43:588–98. doi: 10.1016/j.molimm.2005.04.013
31. Rhodes DA, Ihrke G, Reinicke AT, Malcherek G, Towey M, Isenberg DA, et al. The 52 000 MW Ro/SS-A autoantigen in Sjogren’s syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology. (2002) 106:246–56. doi: 10.1046/j.1365-2567.2002.01417.x
32. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem. (2001) 276:16469–77. doi: 10.1074/jbc.M100350200
33. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. (2000) 406:267–73. doi: 10.1038/35018508
34. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci USA. (2015) 112:833– 8. doi: 10.1073/pnas.1418812112
35. Duncan AR, Winter G. The binding site for C1q on IgG. Nature. (1988) 332:738–40. doi: 10.1038/332738a0
36. Ugurlar D, Howes SC, de Kreuk BJ, Koning RI, de Jong RN, Beurskens FJ, et al. Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. Science. (2018) 359:794–7. doi: 10.1126/science.aao4988
37. Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem. (2014) 289:7812–24. doi: 10.1074/jbc.M113.537563
38. Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure. (1998) 6:63–73. doi: 10.1016/S0969-2126(98)00008-2
39. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-A resolution. Biochemistry. (1981) 20:2361–70. doi: 10.1021/bi00512a001
40. Kato K, Lian LY, Barsukov IL, Derrick JP, Kim H, Tanaka R, et al. Model for the complex between protein G and an antibody Fc fragment in solution. Structure. (1995) 3:79–85. doi: 10.1016/S0969-2126(01)00136-8
41. Sprague ER, Wang C, Baker D, Bjorkman PJ. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol. (2006) 4:e148. doi: 10.1371/journal.pbio.0040148
42. Foss S, Watkinson RE, Grevys A, McAdam MB, Bern M, Hoydahl LS, et al. TRIM21 Immune signaling is more sensitive to antibody affinity than its neutralization activity. J Immunol. (2016) 196:3452– 9. doi: 10.4049/jimmunol.1502601
43. Bidgood SR, Tam JC, McEwan WA, Mallery DL, James LC. Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells. Proc Natl Acad Sci USA. (2014) 111:13463–8. doi: 10.1073/pnas.1410980111
44. McEwan WA, Hauler F, Williams CR, Bidgood SR, Mallery DL, Crowther RA, et al. Regulation of virus neutralization and the persistent fraction by TRIM21. J Virol. (2012) 86:8482–91. doi: 10.1128/JVI.00728-12
45. Fletcher AJ, James LC. Coordinated neutralization and immune activation by the cytosolic antibody receptor TRIM21. J Virol. (2016) 90:4856– 9. doi: 10.1128/JVI.00050-16
46. Fletcher AJ, Mallery DL, Watkinson RE, Dickson CF, James LC. Sequential ubiquitination and deubiquitination enzymes synchronize the dual sensor and effector functions of TRIM21. Proc Natl Acad Sci USA. (2015) 112:10014–9. doi: 10.1073/pnas.1507534112
47. Hauler F, Mallery DL, McEwan WA, Bidgood SR, James LC. AAA ATPase p97/VCP is essential for TRIM21-mediated virus neutralization. Proc Natl Acad Sci USA. (2012) 109:19733–8. doi: 10.1073/pnas.12106 59109
48. Watkinson RE, McEwan WA, Tam JC, Vaysburd M, James LC. TRIM21 Promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus. PLoS Pathog. (2015) 11:e1005253. doi: 10.1371/journal.ppat.1005253
49. Vaysburd M, Watkinson RE, Cooper H, Reed M, O’Connell K, Smith J, et al. Intracellular antibody receptor TRIM21 prevents fatal viral infection. Proc Natl Acad Sci USA. (2013) 110:12397–401. doi: 10.1073/pnas.1301918110
50. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol. (1999) 29:2819–25. doi: 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6
51. Bournazos S, Ravetch JV. Fcgamma receptor function and the design of vaccination strategies. Immunity. (2017) 47:224– 33. doi: 10.1016/j.immuni.2017.07.009
52. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. (2008) 8:34–47. doi: 10.1038/nri2206
53. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. EMBO J. (2001) 20:2140– 51. doi: 10.1093/emboj/20.9.2140
54. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology. (2006) 349:300–15. doi: 10.1016/j.virol.2005.12.040
55. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA. (2006) 103:7465– 70. doi: 10.1073/pnas.0510483103
56. Fletcher AJ, Vaysburd M, Maslen S, Zeng J, Skehel JM, Towers GJ, et al. Trivalent RING assembly on retroviral capsids activates TRIM5 ubiquitination and innate immune signaling. Cell Host Microbe. (2018) 24:761–75 e6. doi: 10.1016/j.chom.2018.10.007
57. Yudina Z, Roa A, Johnson R, Biris N, de Souza Aranha Vieira DA, Tsiperson V, et al. RING dimerization links higher-order assembly of TRIM5alpha to synthesis of K63-linked polyubiquitin. Cell Rep. (2015) 12:788–97. doi: 10.1016/j.celrep.2015.06.072
58. Sanchez JG, Chiang JJ, Sparrer KMJ, Alam SL, Chi M, Roganowicz MD, et al. Mechanism of TRIM25 catalytic activation in the antiviral RIG-I pathway. Cell Rep. (2016) 16:1315–25. doi: 10.1016/j.celrep.2016.06.070
59. Dickson C, Fletcher AJ, Vaysburd M, Yang JC, Mallery DL, Zeng J, et al. Intracellular antibody signalling is regulated by phosphorylation of the Fc receptor TRIM21. Elife. (2018) 7:32660. doi: 10.7554/eLife. 32660
60. Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. (2015) 347:aaa2630. doi: 10.1126/science.aaa2630
61. Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, et al. Antibody-antigen kinetics constrain intracellular humoral immunity. Sci Rep. (2016) 6:37457. doi: 10.1038/srep37457
62. Ng PML, Kaliaperumal N, Lee CY, Chin WJ, Tan HC, Au VB, et al. Enhancing antigen cross-presentation in human monocyte-derived dendritic cells by recruiting the intracellular Fc receptor TRIM21. J Immunol. (2019) 2019:ji1800462. doi: 10.4049/jimmunol.1800462
63. Monteith AJ, Kang S, Scott E, Hillman K, Rajfur Z, Jacobson K, et al. Defects in lysosomal maturation facilitate the activation of innate sensors in systemic lupus erythematosus. Proc Natl Acad Sci USA. (2016) 113:E2142– 51. doi: 10.1073/pnas.1513943113
64. Fan W, Zhang D, Qian P, Qian S, Wu M, Chen H, et al. Swine TRIM21 restricts FMDV infection via an intracellular neutralization mechanism. Antiviral Res. (2016) 127:32–40. doi: 10.1016/j.antiviral.2016. 01.004
65. Greber UF. Virus and host mechanics support membrane penetration and cell entry. J Virol. (2016) 90:3802–5. doi: 10.1128/JVI.02568-15
66. Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ, et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther. (2002) 13:311–20. doi: 10.1089/10430340252769824
67. Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol. (2012) 86:625– 9. doi: 10.1128/JVI.06254-11
68. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. (2007) 81:4654–63. doi: 10.1128/JVI.02696-06
69. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. (2004) 11:351–7. doi: 10.1128/CDLI.11.2.351-357.2004
70. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. (2018) 20:e3015. doi: 10.1002/jgm.3015
71. Crystal RG. Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther. (2014) 25:3–11. doi: 10.1089/hum.2013.2527
72. Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, et al. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS ONE. (2011) 6:e18526. doi: 10.1371/journal.pone.0018526
73. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, Yu QC, et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol. (2002) 76:5711–9. doi: 10.1128/JVI.76.11.5711-5719.2002
74. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol. (2007) 81:6594–604. doi: 10.1128/JVI.02497-06
75. + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol. (2004) 78:2666– 73. doi: 10.1128/JVI.78.6.2666-2673.2004
76. Klasse PJ. Collusion between neutralizing antibodies and other immune factions in the destruction of adenoviral vectors. Proc Natl Acad Sci USA. (2018) 115:10201–3. doi: 10.1073/pnas.1814275115
77. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. (2005) 12:427– 36. doi: 10.1038/sj.gt.3302347
78. + T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA. (2012) 109:E3503– 12. doi: 10.1073/pnas.1208972109
79. Crystal RG, Harvey BG, Wisnivesky JP, O’Donoghue KA, Chu KW, Maroni J, et al. Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. (2002) 13:65– 100. doi: 10.1089/10430340152712647
80. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. (2009) 96:151–7. doi: 10.1016/j.ymgme.2008.12.016
81. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. (2009) 284:12845– 52. doi: 10.1074/jbc.M808759200
82. Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. (2011) 286:15317–31. doi: 10.1074/jbc.M110.209296
83. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. (2013) 80:402– 14. doi: 10.1016/j.neuron.2013.07.046
84. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. (2007) 27:9115–29. doi: 10.1523/JNEUROSCI.2361-07.2007
85. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. (2011) 286:34457–67. doi: 10.1074/jbc.M111.229633
86. Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS ONE. (2015) 10:e0125614. doi: 10.1371/journal.pone.0125614
87. Hultqvist G, Syvanen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. (2017) 7:308–18. doi: 10.7150/thno.17155
88. Neves V, Aires-da-Silva F, Corte-Real S, Castanho MARB. Antibody approaches to treat brain diseases. Trends Biotechnol. (2016) 34:36– 48. doi: 10.1016/j.tibtech.2015.10.005
89. Jansen LE, Black BE, Foltz DR, Cleveland DW. Propagation of centromeric chromatin requires exit from mitosis. J Cell Biol. (2007) 176:795– 805. doi: 10.1083/jcb.200701066
90. Smoak EM, Stein P, Schultz RM, Lampson MA, Black BE. Long-term retention of CENP-A nucleosomes in mammalian oocytes underpins transgenerational inheritance of centromere identity. Curr Biol. (2016) 26:1110–6. doi: 10.1016/j.cub.2016.02.061
91. Castro-Dopico T, Dennison TW, Ferdinand JR, Mathews RJ, Fleming A, Clift D, et al. Anti-commensal IgG drives intestinal inflammation and type 17 immunity in ulcerative colitis. Immunity. (2019) 50:1099–114 e10. doi: 10.1016/j.immuni.2019.02.006
92. Mehlmann LM, Uliasz TF, Lowther KM. SNAP23 is required for constitutive and regulated exocytosis in mouse oocytes. Biol Reprod. (2019) 2019:562843. doi: 10.1101/562843
93. Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol. (2011) 11:788–98. doi: 10.1038/nri3087
94. Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol. (2010) 10:123–30. doi: 10.1038/nri2690
95. Chen X, Liu M, Lou H, Lu Y, Zhou MT, Ou R, et al. Degradation of endogenous proteins and generation of a null-like phenotype in zebrafish using Trim-Away technology. Genome Biol. (2019) 20:19. doi: 10.1186/s13059-019-1624-4
96. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I—Molecular mechanisms of activation and regulation. Front Immunol. (2015) 6:262. doi: 10.3389/fimmu.2015. 00262
97. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. (2015) 6:257. doi: 10.3389/fimmu.2015.00257
98. Watkinson RE, McEwan WA, James LC. Intracellular antibody immunity. J Clin Immunol. (2014) 34 (Suppl. 1):S30–4. doi: 10.1007/s10875-014-0017-4
99. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. (1997) 275:1320–3. doi: 10.1126/science.275.5304.1320
100. Bai M, Campisi L, Freimuth P. Vitronectin receptor antibodies inhibit infection of HeLa and A549 cells by adenovirus type 12 but not by adenovirus type 2. J Virol. (1994) 68:5925–32.
101. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. (1993) 73:309–19. doi: 10.1016/0092-8674(93)90231-E
102. Luisoni S, Suomalainen M, Boucke K, Tanner LB, Wenk MR, Guan XL, et al. Co-option of membrane wounding enables virus penetration into cells. Cell Host Microbe. (2015) 18:75–85. doi: 10.1016/j.chom.2015.06.006
103. Burckhardt CJ, Suomalainen M, Schoenenberger P, Boucke K, Hemmi S, Greber UF. Drifting motions of the adenovirus receptor CAR and immobile integrins initiate virus uncoating and membrane lytic protein exposure. Cell Host Microbe. (2011) 10:105–17. doi: 10.1016/j.chom.2011.07.006
104. Maier O, Marvin SA, Wodrich H, Campbell EM, Wiethoff CM. Spatiotemporal dynamics of adenovirus membrane rupture and endosomal escape. J Virol. (2012) 86:10821–8. doi: 10.1128/JVI.01428-12
105. Bremner KH, Scherer J, Yi J, Vershinin M, Gross SP, Vallee RB. Adenovirus transport via direct interaction of cytoplasmic dynein with the viral capsid hexon subunit. Cell Host Microbe. (2009) 6:523– 35. doi: 10.1016/j.chom.2009.11.006
106. Leopold PL, Kreitzer G, Miyazawa N, Rempel S, Pfister KK, Rodriguez-Boulan E, et al. Dynein-and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther. (2000) 11:151–65. doi: 10.1089/10430340050016238
107. Suomalainen M, Nakano MY, Keller S, Boucke K, Stidwill RP, Greber UF. Microtubule-dependent plus-and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol. (1999) 144:657–72. doi: 10.1083/jcb.14 4.4.657
108. Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF. Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol. (2001) 3:1092–100. doi: 10.1038/ncb1201-1092
109. Cassany A, Ragues J, Guan T, Begu D, Wodrich H, Kann M, et al. Nuclear import of adenovirus DNA involves direct interaction of hexon with an N-terminal domain of the nucleoporin Nup214. J Virol. (2015) 89:1719–30. doi: 10.1128/JVI.02 639-14
110. Schmid M, Ernst P, Honegger A, Suomalainen M, Zimmermann M, Braun L, et al. Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun. (2018) 9:450. doi: 10.1038/s41467-017-0 2707-6
111. Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Grutter MG, et al. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci USA. (2013) 110:E869–77. doi: 10.1073/pnas.12136 53110
112. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Tailor P, et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol. (2007) 179:26–30. doi: 10.4049/jimmunol.179.1.26
113. Yang K, Shi HX, Liu XY, Shan YF, Wei B, Chen S, et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol. (2009) 182:3782–92. doi: 10.4049/jimmunol. 0803126
114. Wada K, Niida M, Tanaka M, Kamitani T. Ro52-mediated monoubiquitination of IKK{beta} down-regulates NF-{kappa}B signalling. J Biochem. (2009) 146:821–32. doi: 10.1093/jb/mvp127
115. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol. (2008) 181:1780–6. doi: 10.4049/jimmunol.181.3.1780
116. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, et al. Self protection from anti-viral responses– Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS ONE. (2010) 5:e11776. doi: 10.1371/journal.pone.0011776
117. Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol. (2013) 14:172–8. doi: 10.1038/ni.2492
118. Sadanand S, Das J, Chung AW, Schoen MK, Lane S, Suscovich TJ, et al. Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. AIDS. (2018) 32:443–50. doi: 10.1097/QAD.00000000000 01716
119. Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, et al. Independent evolution of Fc-and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol. (2014) 44:2925–37. doi: 10.1002/eji.2013 44305
120. Yates NL, Lucas JT, Nolen TL, Vandergrift NA, Soderberg KA, Seaton KE, et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS. (2011) 25:2089–97. doi: 10.1097/QAD.0b013e328 34b348e
121. Damelang T, Rogerson SJ, Kent SJ, Chung AW. Role of IgG3 in Infectious Diseases. Trends Immunol. (2019) 40:197–211. doi: 10.1016/j.it.2019.01.005
122. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. (2008) 21:704–15. doi: 10.1128/CMR. 00052-07
123. Chigbu DI, Labib BA. Pathogenesis and management of adenoviral keratoconjunctivitis. Infect Drug Resist. (2018) 11:981–93. doi: 10.2147/IDR.S162669
124. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. (2011) 364:1897–908. doi: 10.1056/NEJMoa1102673
125. Sivertsen MS, Jorstad OK, Grevys A, Foss S, Moe MC, Andersen JT. Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties. Sci Rep. (2018) 8:2101. doi: 10.1038/s41598-018-20525-8